Kiran Mazumdar-Shaw accompanied her niece in ringing the opening bell at the Nasdaq headquarters in New York City, marking a ...

Shares of BioAge Labs (BIOA), a biopharmaceutical company focused on obesity drugs, opened 25% above its initial public ...

BioAge Labs (BIOA) shares rallied nearly 30% Thursday after the obesity drug developer made its market debut through an upsized $198M initial public offering. Read more here.

Biocon founder and chairperson Kiran Mazumdar-Shaw's niece Claire Mazumdar's company Bicara Therapeutics made its debut at Nasdaq. For the ringing of the opening bell at the stock exchange in New York ...

Black Spade Acquisition II Co (the "Company") (NASDAQ: BSIIU), a special purpose acquisition company ("SPAC"), today ...

Bicara Therapeutics, a clinical-stage biopharmaceutical company, focuses on brining transformative bifunctional therapies for ...

SoFi Technologies (NASDAQ: SOFI) made its public debut on June 1 ... giving SoFi the tools to take numerous financial ...

Starbucks' valuation and forecasts are not compelling enough to take this turnaround risk. Learn why SBUX stock is a Sell.

Impending union strike at ports could boost pricing leverage for industrial REITs like Terreno Realty Trust and Lineage, with ...

Shares of BioAge Labs opened 25% above their initial public offering price on Thursday in a strong debut for the weight-loss drug developer against the backdrop of surging investor enthusiasm.

As of the termination date, the ATM program has generated total gross proceeds of approximately US$1.77 million. The Company views this as an opportunity to explore more favorable financing options ...